Your browser doesn't support javascript.
loading
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.
Mao, Yimin; Ma, Shiwu; Liu, Chenghai; Liu, Xiaoyan; Su, Minghua; Li, Dongliang; Li, Yiling; Chen, Gongying; Chen, Jun; Chen, Jinjun; Zhao, Jingmin; Guo, Xiaoyan; Tang, Jieting; Zhuge, Yuzheng; Xie, Qing; Xie, Wen; Lai, Rongtao; Cai, Dachuan; Cai, Qingxian; Zhi, Yang; Li, Xiaoyun.
Afiliación
  • Mao Y; Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, NHC Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Shanghai, 200001, China. maoym11968@163.com.
  • Ma S; Department of Infectious Diseases, The 920th Hospital of Chinese PLA Joint Logistics Support Force, Kunming, 650032, Yunnan, China.
  • Liu C; Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Liu X; Department of Pharmacy, Huangpu Branch of the 9th People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.
  • Su M; Department of Infectious Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
  • Li D; Department of Hepatobiliary Medicine, The 900th Hospital of Chinese PLA Joint Logistics Support Force, Fuzhou, 350025, Fujian, China.
  • Li Y; Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
  • Chen G; Department of Liver Diseases, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, China.
  • Chen J; Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, 518112, Guangdong, China.
  • Chen J; Hepatology Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
  • Zhao J; Department of Pathology and Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Guo X; Department of Gastroenterology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.
  • Tang J; Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, NHC Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Shanghai, 200001, China.
  • Zhuge Y; Department of Gastroenterology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.
  • Xie Q; Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
  • Xie W; Center of Liver Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100088, China.
  • Lai R; Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
  • Cai D; Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
  • Cai Q; Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, 518112, Guangdong, China.
  • Zhi Y; Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, NHC Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Shanghai, 200001, China.
  • Li X; Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, NHC Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Shanghai, 200001, China.
Hepatol Int ; 18(2): 384-419, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38402364
ABSTRACT
Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fallo Hepático Agudo / Enfermedad Hepática Inducida por Sustancias y Drogas / Antineoplásicos País/Región como asunto: Asia Idioma: En Revista: Hepatol Int Año: 2024 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fallo Hepático Agudo / Enfermedad Hepática Inducida por Sustancias y Drogas / Antineoplásicos País/Región como asunto: Asia Idioma: En Revista: Hepatol Int Año: 2024 Tipo del documento: Article País de afiliación: China